Zimmer Biomet to Acquire Monogram Technologies, Enhancing Robotic Surgery Solutions

Zimmer Biomet Enters Definitive Agreement to Merge with Monogram Technologies

In a significant step towards advancing robotic surgery, Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) has announced a definitive agreement to acquire Monogram Technologies Inc. (NASDAQ: MGRM) in a move set to redefine orthopedic care. This acquisition is expected to create one of the most comprehensive portfolios of orthopedic robotic and navigation technologies, effectively addressing the diverse needs of surgeons worldwide.

The agreement entails an upfront cash payment of $4.04 per share for Monogram, with an equity value reaching approximately $177 million. Additionally, Monogram shareholders are poised to receive a contingent value right (CVR), allowing access to further cash options upon achieving specific product and revenue milestones by 2030. This merger has gained unanimous approval from both firms' boards, marking a pivotal moment for both companies in the medical technology landscape.

Advancements in Robotic Surgery Technology

With Monogram's innovative semi- and fully autonomous robotic technologies, Zimmer Biomet is set to augment its ROSA® Robotics platform—currently a cornerstone of its offerings. One of the notable innovations from Monogram is AI-navigated total knee arthroplasty (TKA) robotic technology, which received FDA clearance in March 2025 and is anticipated to be commercialized by 2027. Additionally, plans for a fully autonomous version of this technology could significantly enhance safety, efficiency, and surgical outcomes in future orthopedic procedures.

Zimmer Biomet's Chairman and CEO, Ivan Tornos, expressed excitement about the strategic acquisition, stating, “Monogram's technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics.” He emphasized that this collaboration will empower Zimmer Biomet to deliver fully autonomous surgical robots, thus setting a new industry standard for orthopedic care.

Benefits for Surgeons and Patients Alike

The strategic integration of Monogram’s robotics into Zimmer Biomet's expansive suite will enable diverse surgical solutions tailored to varied surgeon preferences. Zimmer Biomet currently offers imageless robotics, AI-based navigation, and a comprehensive array of enabling technologies, and the addition of Monogram’s advancements further solidifies its leadership in the orthopedic field. This portfolio allows compatibility with numerous surgical techniques, ensuring the optimal support for surgeons both pre-, intra- and post-operatively.

“Since our inception, we have been focused on advancing orthopedic robotics. Joining forces with Zimmer Biomet allows us to leverage their extensive expertise and global scale,” noted Monogram's CEO, Benjamin Sexson. This merger not only promises to enhance the surgical experience but also reinforces the goal of improving patient outcomes through innovation.

Future Prospects

In terms of financial performance, Zimmer Biomet anticipates that the acquisition will initially be neutral concerning adjusted earnings per share through 2025-2027, with expectations of accretion starting in 2028. This forecast is bolstered by anticipated revenue growth stemming from enhanced robotic knee procedure adoption in the U.S. and the broader reach of Zimmer Biomet’s global offerings in the orthopedic market.

The transaction is subject to regulatory approvals and shareholder consent, with plans for completion slated for later this year. Morgan Stanley & Co. LLC will serve as the financial advisor for Zimmer Biomet, while Wells Fargo Securities, LLC will advise Monogram on the merger.

With over 90 years of innovative medical technology experience, Zimmer Biomet’s commitment to advancing healthcare and optimizing patient outcomes through cutting-edge solutions remains steadfast. The coming years should see exciting developments as the integrated technologies from this acquisition begin to emerge in clinical settings.

This merger marks an era where orthopedic surgery may be rapidly evolving with robotics at the forefront, benefiting both the surgeons who perform these complex operations and the patients who undergo them.

For further information about Zimmer Biomet’s ongoing efforts in robotic surgery and its expansive product portfolio, please continue to follow updates and news from both Zimmer Biomet and Monogram Technologies.